Bliss GVS Pharma Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Los beneficios de Bliss GVS Pharma han disminuido a una tasa media anual de -13.9%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 14.8% anualmente. Los ingresos han ido creciendo a una tasa media de 1.1% al año. La rentabilidad financiera de Bliss GVS Pharma es de 9.3%, y sus márgenes netos son de 11.6%.
Información clave
-14.2%
Tasa de crecimiento de los beneficios
-14.4%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 17.5% |
| Tasa de crecimiento de los ingresos | -0.8% |
| Rentabilidad financiera | 8.1% |
| Margen neto | 9.4% |
| Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Right But Growth Is Lacking
Apr 27
Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Feb 20There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding
Jan 26Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Jul 14Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50
Sep 11Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50
Aug 28These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well
May 21Estimating The Intrinsic Value Of Bliss GVS Pharma Limited (NSE:BLISSGVS)
Apr 08A Look At Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Returns
Mar 18Here's How We Evaluate Bliss GVS Pharma Limited's (NSE:BLISSGVS) Dividend
Feb 25Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet
Feb 08What Type Of Shareholders Make Up Bliss GVS Pharma Limited's (NSE:BLISSGVS) Share Registry?
Jan 21Do Its Financials Have Any Role To Play In Driving Bliss GVS Pharma Limited's (NSE:BLISSGVS) Stock Up Recently?
Jan 08How Is Bliss GVS Pharma's (NSE:BLISSGVS) CEO Paid Relative To Peers?
Dec 26
Did Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Deserve to Gain 14%?
Dec 13Should You Use Bliss GVS Pharma's (NSE:BLISSGVS) Statutory Earnings To Analyse It?
Nov 30Bliss GVS Pharma Limited (NSE:BLISSGVS) Insiders Increased Their Holdings
Nov 18Does Bliss GVS Pharma Limited (NSE:BLISSGVS) Have A Place In Your Dividend Portfolio?
Nov 06Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?
Oct 25Is Bliss GVS Pharma Limited's (NSE:BLISSGVS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Oct 07How Much Is Bliss GVS Pharma Limited (NSE:BLISSGVS) CEO Getting Paid?
Sep 19What Is The Ownership Structure Like For Bliss GVS Pharma Limited (NSE:BLISSGVS)?
Sep 04Have Insiders Been Buying Bliss GVS Pharma Limited (NSE:BLISSGVS) Shares?
Aug 17The Bliss GVS Pharma (NSE:BLISSGVS) Share Price Has Gained 43% And Shareholders Are Hoping For More
Aug 04Fewer Investors Than Expected Jumping On Bliss GVS Pharma Limited (NSE:BLISSGVS)
Aug 04Bliss GVS Pharma (NSE:BLISSGVS) Seems To Use Debt Quite Sensibly
Jul 21Should You Use Bliss GVS Pharma's (NSE:BLISSGVS) Statutory Earnings To Analyse It?
Jul 06Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Bliss GVS Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 24 | 7,990 | 755 | 956 | 0 |
| 31 Dec 23 | 7,569 | 879 | 1,234 | 0 |
| 30 Sep 23 | 7,619 | 883 | 1,213 | 0 |
| 30 Jun 23 | 7,224 | 598 | 1,190 | 0 |
| 31 Mar 23 | 7,516 | 709 | 1,160 | 0 |
| 31 Dec 22 | 7,339 | 871 | 1,284 | 0 |
| 30 Sep 22 | 7,444 | 91 | 1,256 | 0 |
| 30 Jun 22 | 7,680 | 165 | 1,235 | 0 |
| 31 Mar 22 | 7,475 | 150 | 1,045 | 0 |
| 31 Dec 21 | 7,124 | 17 | 896 | 0 |
| 30 Sep 21 | 6,602 | 773 | 876 | 0 |
| 30 Jun 21 | 6,158 | 766 | 698 | 0 |
| 31 Mar 21 | 5,772 | 685 | 827 | 0 |
| 31 Dec 20 | 5,650 | 710 | 763 | 0 |
| 30 Sep 20 | 5,487 | 692 | 730 | 0 |
| 30 Jun 20 | 6,073 | 797 | 582 | 0 |
| 31 Mar 20 | 6,893 | 973 | 684 | 0 |
| 31 Dec 19 | 8,136 | 1,066 | 835 | 0 |
| 30 Sep 19 | 8,861 | 1,087 | 805 | 0 |
| 30 Jun 19 | 9,044 | 1,192 | 525 | 0 |
| 31 Mar 19 | 8,986 | 1,237 | 748 | 0 |
| 31 Dec 18 | 3,788 | 623 | 234 | 0 |
| 30 Sep 18 | 3,543 | 543 | 300 | 0 |
| 30 Jun 18 | 3,521 | 469 | 369 | 0 |
| 31 Mar 18 | 3,720 | 297 | 432 | 0 |
| 31 Dec 17 | 9,063 | 1,098 | 1,669 | 0 |
| 30 Sep 17 | 9,423 | 1,053 | 1,659 | 0 |
| 30 Jun 17 | 8,843 | 860 | 1,627 | 0 |
| 31 Mar 17 | 4,033 | 509 | 654 | 0 |
| 31 Dec 16 | 6,711 | 664 | 944 | 0 |
| 30 Sep 16 | 5,755 | 742 | 853 | 0 |
| 30 Jun 16 | 5,911 | 836 | 370 | 0 |
| 31 Mar 16 | 5,469 | 825 | 782 | 0 |
| 31 Mar 15 | 4,071 | 599 | 764 | 0 |
| 31 Mar 14 | 3,446 | 410 | 828 | 0 |
Ingresos de calidad: BLISSGVS tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (9.4%) de BLISSGVS son superiores a los del año pasado (9.4%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de BLISSGVS han disminuido en un 13.9% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de BLISSGVS en el último año (0.9%) supera su media de 5 años (-13.9% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de BLISSGVS en el último año (0.9%) no superó al de la industria Pharmaceuticals 23.8%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de BLISSGVS (9.3%) se considera baja.